Compounds > pd168393

pd168393 and gefitinib

pd168393 has been researched along with gefitinib in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balk, SP; Didonato, M; Flatauer, L; Gray, NS; Hur, W; Jiang, X; Kim, S; Larson, B; Mason, DE; Nagle, A; Peters, EC; Suzuki, M; Valente, D; Velentza, A; Warmuth, M; Zagorska, A; Zhang, J1
Da Settimo, F; La Motta, C; Martinelli, A; Nerini, E; Sartini, S; Tuccinardi, T1
Alfieri, RR; Ardizzoni, A; Bordi, F; Carmi, C; Cavazzoni, A; Galetti, M; La Monica, S; Lodola, A; Mor, M; Petronini, PG; Rivara, S; Silva, C; Vacondio, F; Vezzosi, S1
Aiello, S; Alfieri, RR; Ardizzoni, A; Bordi, F; Carmi, C; Cavazzoni, A; Costantino, G; Galvani, E; Lodola, A; Mor, M; Petronini, PG; Rivara, S; Russo, S; Vacondio, F1
Alfieri, RR; Bassi, M; Carmi, C; Cavazzoni, A; Galvani, E; Lodola, A; Mor, M; Petronini, PG; Rivara, S; Silva, C; Vacondio, F1
Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW1
Claasen, J; Sos, ML; Staratschek-Jox, A; Thomas, RK; Wolf, J; Zander, T1
Lu, C; Mi, LZ; Schürpf, T; Springer, TA; Walz, T1
Choo, J; Chung, HY; Heo, G; Im, E; Jung, JH; Jung, Y; Kim, DH; Kim, MJ; Kim, SJ; Kim, W; Lee, Y; Moon, HR; Noh, TH; Son, S1

Other Studies

9 other study(ies) available for pd168393 and gefitinib

ArticleYear
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
    Bioorganic & medicinal chemistry letters, 2008, Nov-15, Volume: 18, Issue:22

    Topics: Animals; Cysteine; ErbB Receptors; Mice; Molecular Structure; Morpholines; Protein-Tyrosine Kinases; Quinazolines; Sequence Homology, Amino Acid

2008
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.
    Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4

    Topics: Computational Biology; Computer Simulation; Databases, Protein; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Protein Binding; Quantitative Structure-Activity Relationship

2009
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
    Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5

    Topics: Aniline Compounds; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Quinazolines; Structure-Activity Relationship

2010
Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides.
    Journal of medicinal chemistry, 2012, Mar-08, Volume: 55, Issue:5

    Topics: Amides; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Phosphorylation; Propionates; Quinazolines; Quinolines; Structure-Activity Relationship

2012
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors.
    Bioorganic & medicinal chemistry letters, 2013, Oct-01, Volume: 23, Issue:19

    Topics: Aniline Compounds; Cell Cycle Checkpoints; Cell Line, Tumor; Chemistry, Pharmaceutical; ErbB Receptors; Humans; Inhibitory Concentration 50; Molecular Structure; Phosphorylation; Quinazolines; Time Factors

2013
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
    Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines

2006
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Farnesyltranstransferase; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Phosphatidylinositols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Sirolimus

2008
Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
    The Journal of biological chemistry, 2012, Nov-02, Volume: 287, Issue:45

    Topics: Animals; Binding Sites; Blotting, Western; Cell Line; Cross-Linking Reagents; Disulfides; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Microscopy, Electron; Mutation; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines

2012
Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.
    Cell death & disease, 2018, 08-29, Volume: 9, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, src; HCT116 Cells; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; src-Family Kinases

2018